Glenzocimab
Glenzocimab (ACT017), a Fab fragment of a humanized anti-GPVI monoclonal antibody, demonstrated inhibition of collagen-induced platelet aggregation in an ischemic stroke model and has been studied in acute ischemic stroke and cerebral thrombosis.
Product Specifications
CAS Number
2101829-58-5
Stability
≥ 2 years
Purity
>98% (HPLC)
Molecular Formula
——
Notes
Research use only, not for human use.
Receptor
Others
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY426675 100 µg
FOXD4L5 (NM_001126334) Human Over-expression Lysate
Sign In for Pricing
View Details 
12113114 3x 1.0 µg
Ap3d1 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse)
Sign In for Pricing
View Details AS16 3690-HRP 40 µg
Anti-Cas9 | CRISPR-associated endonuclease 9 (polyclonal) - HRP conjugated 40 µg
Sign In for Pricing
View Details